Myriad Genetics (MYGN) Stock Statistics & Valuation Metrics

Myriad Genetics has a market cap or net worth of $744.75M. The enterprise value is $1.28B.

Myriad Genetics has 92.17M shares outstanding. The number of shares has decreased by -2.65% in one year.

Myriad Genetics’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -25.67%.

The current PE Ratio of Myriad Genetics is -6.02. Myriad Genetics’s PEG ratio is -0.05.

In the last 12 months, Myriad Genetics had revenue of $823.60M and earned -$116.00M in profits. Earnings per share was -$1.30.

In the last 12 months, operating cash flow was -$70.00M and capital expenditures -$37.30M, giving a free cash flow of -$107.30M billion.

Myriad Genetics pays an annual dividend of $1.75, resulting in a dividend yield of

Myriad Genetics upcoming earnings date is May 1, 2025, TBA.

Myriad Genetics as a current ratio of 2.01, with Debt / Equity ratio of 0.19

In the past 12 months, Myriad Genetics has paid -$600.00K in taxes.

Myriad Genetics EV to EBITDA ratio is -8.62, with an EV/FCF ratio of -8.71.

Myriad Genetics has $99.90M in cash and marketable securities with $143.10M in debt, giving a net cash position of $43.20M billion.

Gross margin is 68.64%, with operating margin of -34.17%, and net profit margin of -34.96%.

The average price target for Myriad Genetics is $15.79, which is 11.43% higher than the current price. The consensus rating is Hold